

David A Isenberg

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2161950/david-a-isenberg-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

512
papers

33,052
citations

83
h-index

170
g-index

597
ext. papers

38,488
ext. citations

5.8
avg. IF

7.13
L-index

#	Paper	IF	Citations
512	Use of Glomerular CD68+ Cells as a Surrogate Marker for Endocapillary Hypercellularity in Lupus Nephritis.. <i>Kidney International Reports</i> , 2022 , 7, 841-847	4.1	0
511	The origins, evolution and future of the International Myositis Assessment and Clinical Studies Group (IMACS). <i>Clinical and Experimental Rheumatology</i> , 2022 , 40, 214-218	2.2	0
510	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021 , 73, 1231-1235	4.7	10
509	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , 2021	2.4	4
508	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	7
507	Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus : A Randomized Controlled Trial. <i>Annals of Internal Medicine</i> , 2021 ,	8	8
506	Disparity in Peripheral and Renal B-cell Depletion with Rituximab in Systemic Lupus Erythematosus: an Opportunity for Obinutuzumab?. <i>Rheumatology</i> , 2021 ,	3.9	1
505	Fracture risk in systemic lupus erythematosus patients over 28 years. <i>Rheumatology</i> , 2021 , 60, 2765-2773.	3.9	2
504	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021 , 73, 1789-1795	4.7	2
503	Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLE. <i>EBioMedicine</i> , 2021 , 65, 103243	8.8	11
502	Ultrasound to identify systemic lupus erythematosus patients with musculoskeletal symptoms who respond best to therapy: the US Evaluation For mUsculoskeletal Lupus longitudinal multicentre study. <i>Rheumatology</i> , 2021 , 60, 5194-5204	3.9	6
501	What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2059-2068	9.5	2
500	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021 , 30, 1283-1288	2.6	2
499	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2293-2302	9.5	2
498	IgG vs IgG + IgM anti-double stranded DNA measurement: a comparative report for clinical practice. <i>Rheumatology</i> , 2021 , 60, 3951-3952	3.9	0
497	Anti-IFN β Mabs for the treatment of systemic lupus erythematosus. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 519-528	5.4	4
496	Thrombotic antiphospholipid syndrome: A practical guide to diagnosis and management. <i>Thrombosis Research</i> , 2021 , 198, 213-221	8.2	12

495	The use of anti-TNF-alpha therapies for patients with systemic lupus erythematosus. Where are we now?. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 639-647	5.4	5
494	Assessing outcomes in a lupus nephritis cohort over a 40-year period. <i>Rheumatology</i> , 2021 , 60, 1814-1823	3.9	3
493	How COVID-19 is changing rheumatology clinical practice. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 11-15	5.1	12
492	Anti-protein C antibodies and acquired protein C resistance in SLE: novel markers for thromboembolic events and disease activity?. <i>Rheumatology</i> , 2021 , 60, 1376-1386	3.9	4
491	How I treat anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Blood</i> , 2021 , 137, 299-309	2.2	7
490	Childhood-onset of primary Sjögren's syndrome: phenotypic characterization at diagnosis of 158 children. <i>Rheumatology</i> , 2021 , 60, 4558-4567	3.9	4
489	Analysis of trends and causes of death in SLE patients over a 40-years period in a cohort of patients in the United Kingdom. <i>Lupus</i> , 2021 , 30, 702-706	2.6	2
488	Rituximab - The first twenty years. <i>Lupus</i> , 2021 , 30, 371-377	2.6	3
487	Total plaque area and plaque echogenicity are novel measures of subclinical atherosclerosis in patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2021 , 60, 4185-4198	3.9	0
486	Psychosis in systemic lupus erythematosus (SLE): 40-year experience of a specialist centre. <i>Rheumatology</i> , 2021 , 60, 5620-5629	3.9	2
485	Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. <i>Rheumatology</i> , 2021 , 60, 5379-5389	3.9	2
484	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , 2021 , 60, 4737-4747	3.9	5
483	Can we predict if patients will require more than one cycle of rituximab?. <i>Rheumatology</i> , 2021 ,	3.9	2
482	Differential levels of IFN-γ subtypes in autoimmunity and viral infection. <i>Cytokine</i> , 2021 , 144, 155533	4	5
481	Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1835-1846	9.5	11
480	Stratification of Patients With Sjögren's Syndrome and Patients With Systemic Lupus Erythematosus According to Two Shared Immune Cell Signatures, With Potential Therapeutic Implications. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1626-1637	9.5	5
479	CRESS: improving the assessment of disease activity in Sjögren's syndrome. <i>Lancet Rheumatology</i> , 2021 , 3, e534-e535	14.2	
478	Prevalence and outcome of thrombocytopenia in systemic lupus erythematosus: single-centre cohort analysis. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 601-605	2.2	1

477	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 166-174	2.2	0
476	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	5
475	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 133, 166-174	2.2	
474	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020 ,	4.7	2
473	The assessment of patients with the antiphospholipid antibody syndrome: where are we now?. <i>Rheumatology</i> , 2020 , 59, 1489-1494	3.9	2
472	Eric Bywaters a life story: 1 June 1910 to 2 April 2003. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 996-998	4	4
471	Bruton [®] Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?. <i>ImmunoTargets and Therapy</i> , 2020 , 9, 105-110	9	17
470	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1734-1740	9.5	7
469	"Mixed connective tissue disease": a condition in search of an identity. <i>Clinical and Experimental Medicine</i> , 2020 , 20, 159-166	4.9	5
468	Towards Precision Medicine in Systemic Lupus Erythematosus. <i>Pharmacogenomics and Personalized Medicine</i> , 2020 , 13, 39-49	2.1	15
467	Systemic lupus erythematosus: causes and manifestations. <i>Trends in Urology & Men's Health</i> , 2020 , 11, 26-29	0.3	1
466	Attainment of treat-to-target endpoints in SLE patients with high disease activity in the ataccept phase 2b ADDRESS II study. <i>Rheumatology</i> , 2020 , 59, 2930-2938	3.9	12
465	A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE. <i>Rheumatology</i> , 2020 , 59, 2734-2745	3.9	13
464	Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort. <i>Rheumatology</i> , 2020 , 59, 524-533	3.9	10
463	Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. <i>Rheumatology</i> , 2020 , 59, 194-204	3.9	5
462	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020 , 72, 1800-1808	4.7	7
461	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020 , 72, 658-666	9.5	11
460	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020 , 106, 102340	15.5	15

459	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 356-362	2.4	18
458	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , 2020 , 59, 2350-2359	3.9	24
457	Use of direct oral anticoagulants in antiphospholipid syndrome: Reply. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 259-261	15.4	5
456	Biologic therapies for systemic lupus erythematosus: where are we now?. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 597-608	5.3	2
455	Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage. <i>Arthritis Care and Research</i> , 2020 , 72 Suppl 10, 27-46	4.7	7
454	Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders. <i>Frontiers in Immunology</i> , 2020 , 11, 592639	8.4	0
453	Management of anticoagulant-refractory thrombotic antiphospholipid syndrome. <i>Lancet Haematology</i> , 2020 , 7, e613-e623	14.6	4
452	B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?. <i>Lancet Rheumatology</i> , 2020 , 2, e589-e590	14.2	41
451	Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach. <i>Lancet Rheumatology</i> , 2020 , 2, e485-e496	14.2	21
450	Hydroxychloroquine in patients with rheumatic diseases during the COVID-19 pandemic: a letter to clinicians. <i>Lancet Rheumatology</i> , 2020 , 2, e735-e736	14.2	3
449	16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. <i>Lupus</i> , 2020 , 29, 1571-1593	2.6	27
448	Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2126-2137	15.4	30
447	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020 , 47, 72-81	4.1	21
446	Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e90	2.4	6
445	Comparison of Three Classification Criteria Sets for Systemic Lupus Erythematosus: A Study Looking at Links to Outcome and Mortality. <i>Arthritis Care and Research</i> , 2020 , 72, 1611-1614	4.7	16
444	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020 , 72, 67-77	9.5	18
443	Antiphospholipid antibody levels in early systemic lupus erythematosus: are they associated with subsequent mortality and vascular events?. <i>Rheumatology</i> , 2020 , 59, 146-152	3.9	6
442	Outcomes of membranous and proliferative lupus nephritis - analysis of a single-centre cohort with more than 30 years of follow-up. <i>Rheumatology</i> , 2020 , 59, 3314-3323	3.9	3

441	Why do some patients with systemic lupus erythematosus fail to respond to B-cell depletion using rituximab?. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 262-266	2.2	4
440	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 85-94	2.2	1
439	Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis. <i>BMC Rheumatology</i> , 2019 , 3, 32	2.9	7
438	Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. <i>Journal of Rheumatology</i> , 2019 , 46, 492-500	4.1	7
437	Can we validate a clinical score to predict the risk of severe infection in patients with systemic lupus erythematosus? A longitudinal retrospective study in a British Cohort. <i>BMJ Open</i> , 2019 , 9, e028697		13
436	New therapies for systemic lupus erythematosus - past imperfect, future tense. <i>Nature Reviews Rheumatology</i> , 2019 , 15, 403-412	8.1	77
435	E083 Designing a diet interventional study for autoimmune rheumatic disease: asking patients what they think. <i>Rheumatology</i> , 2019 , 58,	3.9	1
434	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome. <i>RMD Open</i> , 2019 , 5, e000885	5.9	9
433	Characterization of a Subset of Patients With Rheumatoid Arthritis for Whom Current Management Strategies are Inadequate. <i>ACR Open Rheumatology</i> , 2019 , 1, 145-155	3.5	1
432	Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1140-1142	2.4	18
431	Recognition and management of systemic lupus erythematosus. <i>The Prescriber</i> , 2019 , 30, 13-20	0.4	
430	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1297-1307	9.5	15
429	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019 , 58, 1259-1267	3.9	5
428	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 374-382	6.1	20
427	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019 , 71, 893-902	4.7	46
426	A case of repetitive myocardial infarction with unobstructed coronaries due to Churg-Strauss syndrome. <i>European Heart Journal - Case Reports</i> , 2019 , 3,	0.9	4
425	Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus Stratification. <i>Scientific Reports</i> , 2019 , 9, 15502	4.9	12
424	Myositis. <i>Contemporary Clinical Neuroscience</i> , 2019 , 787-808	0.1	

423	Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial. <i>BMJ Open</i> , 2019 , 9, e032569	3	21
422	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1010-1012	2.4	4
421	Antinuclear Antibodies, Antibodies to DNA, Histones, and Nucleosomes 2019 , 355-365		0
420	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 281-289	9.5	31
419	Under crossfire: thromboembolic risk in systemic lupus erythematosus. <i>Rheumatology</i> , 2019 , 58, 940-952	3.9	13
418	Comment on: Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab by Eric Morand. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e121	2.4	
417	Recent developments in biologic therapies for the treatment of patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2019 , 58, 382-387	3.9	12
416	Present and novel biologic drugs in primary Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 167-174	2.2	10
415	Review of major endocrine abnormalities in patients with systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 791-796	2.2	3
414	Obituary for Paul Bacon. <i>Rheumatology</i> , 2018 , 57, 943-945	3.9	
413	Very delayed lupus nephritis: a report of three cases and literature review. <i>Lupus Science and Medicine</i> , 2018 , 5, e000241	4.6	1
412	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 393-396	4.1	23
411	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018 , 57, 677-687	3.9	20
410	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1478-1487	4.7	36
409	Advances in systemic lupus erythematosus. <i>Medicine</i> , 2018 , 46, 84-92	0.6	6
408	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. <i>Rheumatology</i> , 2018 , 57, 14-18	3.9	23
407	Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register. <i>Rheumatology</i> , 2018 , 57, 470-479	3.9	47
406	The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. <i>Rheumatology</i> , 2018 , 57, e1-e45	3.9	150

405	CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes. <i>Cellular and Molecular Immunology</i> , 2018 , 15, 158-170	15.4	36
404	Direct Oral Anticoagulants for Thromboprophylaxis in Patients with Antiphospholipid Syndrome. <i>Seminars in Thrombosis and Hemostasis</i> , 2018 , 44, 427-438	5.3	10
403	Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. <i>Rheumatology</i> , 2018 , 57, 125-133	3.9	8
402	Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. <i>Arthritis and Rheumatology</i> , 2018 , 70, 266-276	9.5	114
401	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 1074-1082	6.1	24
400	CD19CD24CD38 B Cells Are Expanded in Juvenile Dermatomyositis and Exhibit a Pro-Inflammatory Phenotype After Activation Through Toll-Like Receptor 7 and Interferon- γ . <i>Frontiers in Immunology</i> , 2018 , 9, 1372	8.4	34
399	Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndrome. <i>Journal of Autoimmunity</i> , 2018 , 93, 114-123	15.5	13
398	Impact of pre-transplant time on dialysis on survival in patients with lupus nephritis. <i>Clinical Rheumatology</i> , 2018 , 37, 2399-2404	3.9	5
397	Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. <i>Rheumatology</i> , 2018 , 57, 1502-1503	3.9	7
396	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018 , 70, 1294-1302	4.7	13
395	PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic Properties of IgG From Patients With the Antiphospholipid Syndrome. <i>Frontiers in Immunology</i> , 2018 , 9, 2413	8.4	8
394	Low Percentage of Signal Regulatory Protein α Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients. <i>Frontiers in Immunology</i> , 2018 , 9, 2865	8.4	6
393	Assessment of Response to B-Cell Depletion Using Rituximab in Cutaneous Lupus Erythematosus. <i>JAMA Dermatology</i> , 2018 , 154, 1432-1440	5.1	27
392	Antiphospholipid Antibodies to Domain I of Beta-2-Glycoprotein I Show Different Subclass Predominance in Comparison to Antibodies to Whole Beta-2-glycoprotein I. <i>Frontiers in Immunology</i> , 2018 , 9, 2244	8.4	8
391	An evaluation of voclosporin for the treatment of lupus nephritis. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1613-1621	4	16
390	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 102-112	2.2	34
389	Rituximab in the treatment of inflammatory myopathies: a review. <i>Rheumatology</i> , 2017 , 56, 26-36	3.9	67
388	Physical activity but not sedentary activity is reduced in primary Sjögren's syndrome. <i>Rheumatology International</i> , 2017 , 37, 623-631	3.6	10

387	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 554-561	2.4	175
386	The use of rituximab in newly diagnosed patients with systemic lupus erythematosus: long-term steroid saving capacity and clinical effectiveness. <i>Lupus Science and Medicine</i> , 2017 , 4, e000182	4.6	23
385	Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1042-1050	2.4	73
384	Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. <i>Rheumatology</i> , 2017 , 56, 1227-1237	3.9	78
383	Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 2017 , 53, 237-264	12.3	30
382	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials	9.5	36
381	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017 , 69, 898-910	9.5	33
380	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Annals of the Rheumatic Diseases</i> , 2017 ,	2.4	65
379	Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2017 , 9, 75-85	3.8	21
378	Thrombocytopenia in the Antiphospholipid Syndrome. <i>Handbook of Systemic Autoimmune Diseases</i> , 2017 , 121-130	0.3	
377	Comment on: Musculoskeletal complication of haematological disease: Reply. <i>Rheumatology</i> , 2017 , 56, 321	3.9	
376	Kidney disease in primary anti-phospholipid antibody syndrome. <i>Rheumatology</i> , 2017 , 56, 1069-1080	3.9	4
375	Mixed connective tissue disease-enigma variations?. <i>Rheumatology</i> , 2017 , 56, 326-333	3.9	11
374	Factor Xa Mediates Calcium Flux in Endothelial Cells and is Potentiated by IgG From Patients With Lupus and/or Antiphospholipid Syndrome. <i>Scientific Reports</i> , 2017 , 7, 10788	4.9	5
373	Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature: Comment. <i>Current Rheumatology Reports</i> , 2017 , 19, 50	4.9	5
372	TRIM21 and the Function of Antibodies inside Cells. <i>Trends in Immunology</i> , 2017 , 38, 916-926	14.4	50
371	The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales. <i>Rheumatology</i> , 2017 , 56, 1041-1043	3.9	1
370	Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 667-676	5.1	9

369	Post Hoc Analysis of the Phase II/III APRIL-SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BlyS and APRIL. <i>Arthritis and Rheumatology</i> , 2017 , 69, 122-130	9.5	26
368	Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long-Term Effects on Serum Immunoglobulins. <i>Arthritis Care and Research</i> , 2017 , 69, 857-866	4.7	36
367	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 287	5.7	1
366	324. LUPUS AND AVASCULAR NECROSIS OF THE BONE: HAS THE INCIDENCE IMPROVED?. <i>Rheumatology</i> , 2017 , 56,	3.9	1
365	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016 , 55, 252-62	3.9	210
364	Musculoskeletal complications of haematological disease. <i>Rheumatology</i> , 2016 , 55, 968-81	3.9	11
363	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. <i>Rheumatology</i> , 2016 , 55, 544-52	3.9	7
362	Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. <i>Lancet Haematology</i> , 2016 , 3, e426-36	14.6	231
361	The diagnosis and management of the haematologic manifestations of lupus. <i>Journal of Autoimmunity</i> , 2016 , 74, 139-160	15.5	53
360	Analysis of Complete Remission in Systemic Lupus Erythematosus Patients Over a 32-Year Period. <i>Arthritis Care and Research</i> , 2016 , 68, 981-7	4.7	42
359	From BILAG to BILAG-based combined lupus assessment-30 years on. <i>Rheumatology</i> , 2016 , 55, 1357-63	3.9	9
358	DNA-damaging autoantibodies and cancer: the lupus butterfly theory. <i>Nature Reviews Rheumatology</i> , 2016 , 12, 429-34	8.1	39
357	Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjögren's syndrome. <i>Rheumatology</i> , 2016 , 55, 1548-55	3.9	45
356	A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus. <i>Immunity</i> , 2016 , 44, 683-697	32.3	205
355	Current pharmacological treatment of idiopathic inflammatory myopathies. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 547-558	3.8	6
354	Measuring IgA Anti- β -Glycoprotein I and IgG/IgA Anti-Domain I Antibodies Adds Value to Current Serological Assays for the Antiphospholipid Syndrome. <i>PLoS ONE</i> , 2016 , 11, e0156407	3.7	50
353	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1932-44	9.5	27
352	Off-label use of rituximab for systemic lupus erythematosus in Europe. <i>Lupus Science and Medicine</i> , 2016 , 3, e000163	4.6	34

351	Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque. <i>Science Immunology</i> , 2016 , 1,	28	28
350	The safety of pharmacological treatment options for lupus nephritis. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1041-54	4.1	4
349	Why do patients with myositis die? A retrospective analysis of a single-centre cohort. <i>Clinical and Experimental Rheumatology</i> , 2016 , 34, 820-826	2.2	13
348	Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?. <i>Rheumatology</i> , 2015 , 54, 655-9	3.9	19
347	Assessment of long-term remission in lupus nephritis patients: a retrospective analysis over 30 years. <i>Rheumatology</i> , 2015 , 54, 1403-7	3.9	16
346	Advances in the treatment of ocular dryness associated with Sjögren's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 2015 , 45, 321-7	5.3	19
345	Risk factors for renal disease in systemic lupus erythematosus and their clinical implications. <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 837-48	5.1	8
344	Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. <i>Rheumatology</i> , 2015 , 54, 2042-50	3.9	46
343	Longer duration of B cell depletion is associated with better outcome. <i>Rheumatology</i> , 2015 , 54, 1876-81	3.9	18
342	IgG anti-apolipoprotein A-1 antibodies in patients with systemic lupus erythematosus are associated with disease activity and corticosteroid therapy: an observational study. <i>Arthritis Research and Therapy</i> , 2015 , 17, 26	5.7	20
341	Anti-factor Xa antibodies in patients with antiphospholipid syndrome and their effects upon coagulation assays. <i>Arthritis Research and Therapy</i> , 2015 , 17, 47	5.7	11
340	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1837-47	9.5	77
339	Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. <i>Arthritis Care and Research</i> , 2015 , 67, 128-35	4.7	31
338	Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosus. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2046-55	9.5	43
337	Belimumab in systemic lupus erythematosus. <i>RMD Open</i> , 2015 , 1, e000011	5.9	14
336	What can we learn from systemic lupus erythematosus pathophysiology to improve current therapy?. <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 1093-107	5.1	3
335	Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study. <i>Lupus Science and Medicine</i> , 2015 , 2, e000104	4.6	39
334	B-cell survival factors in autoimmune rheumatic disorders. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2015 , 7, 122-51	3.8	23

333	Clinical trials perception in rheumatology patients: experience from a single rheumatology tertiary center. <i>Journal of Rheumatology</i> , 2015 , 42, 988-93	4.1	1
332	Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of β -glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. <i>Rheumatology</i> , 2015 , 54, 722-7	3.9	49
331	Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 2006-15	2.4	189
330	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1530-6	2.4	51
329	Biologic treatment in Sjögren's syndrome. <i>Rheumatology</i> , 2015 , 54, 219-30	3.9	42
328	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1706-13	2.4	250
327	Systemic lupus erythematosus and the role of the GP. <i>The Prescriber</i> , 2015 , 26, 31-35	0.4	
326	Profile of atacicept and its potential in the treatment of systemic lupus erythematosus. <i>Drug Design, Development and Therapy</i> , 2015 , 9, 1331-9	4.4	22
325	EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015 , 1, e000022	5.9	150
324	Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. <i>Rheumatology</i> , 2015 , 54, 1050-5	3.9	17
323	Asymmetric appearance of immunological abnormalities in close relatives of patients with systemic lupus erythematosus. <i>Clinical Immunology</i> , 2015 , 157, 226-7	9	1
322	Rituximab: the Lupus Journey. <i>Current Treatment Options in Rheumatology</i> , 2015 , 1, 30-41	1.3	11
321	Rivaroxaban Limits Complement Activation Compared to Warfarin in Antiphospholipid Syndrome Patients with Venous Thromboembolism. <i>Blood</i> , 2015 , 126, 2328-2328	2.2	3
320	The Pathophysiology of Antiphospholipid Syndrome. <i>The Open Urology & Nephrology Journal</i> , 2015 , 8, 2-9	0.2	2
319	Serum nitrated nucleosome levels in patients with systemic lupus erythematosus: a retrospective longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2014 , 16, R48	5.7	4
318	Advances in systemic lupus erythematosus. <i>Medicine</i> , 2014 , 42, 126-133	0.6	5
317	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 138-42	2.4	83
316	Overview of biologic therapies in autoimmune rheumatic diseases. <i>Medicine</i> , 2014 , 42, 184-187	0.6	1

315	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 958-67	2.4	388
314	Systemic lupus erythematosus in 2013. Taking a closer look at biologic therapy for SLE. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 71-2	8.1	9
313	Health-related utility values of patients with primary Sjögren's syndrome and its predictors. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1362-8	2.4	63
312	Vaccines and biologics. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1446-54	2.4	22
311	Recent advances in the treatment of systemic lupus erythematosus. <i>International Journal of Clinical Rheumatology</i> , 2014 , 9, 89-100	1.5	
310	American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. <i>Journal of Rheumatology</i> , 2014 , 41, 875-80	4.1	17
309	A comparison of the outcome of adolescent and adult-onset systemic lupus erythematosus. <i>Rheumatology</i> , 2014 , 53, 1130-5	3.9	36
308	Why and how should we measure disease activity and damage in lupus?. <i>Presse Medicale</i> , 2014 , 43, e151-62	6.2	16
307	25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. <i>Arthritis Care and Research</i> , 2014 , 66, 1167-76	4.7	43
306	A retrospective study of long-term outcomes in 152 patients with primary Sjögren's syndrome: 25-year experience. <i>Clinical Medicine</i> , 2014 , 14, 322-322	1.9	78
305	Systemic lupus erythematosus. <i>Lancet, The</i> , 2014 , 384, 1878-1888	4.0	439
304	A8.13 Changes in the relationship between BAFF, BAFF-R and B cell phenotype following rituximab in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A81.1-A81	2.4	1
303	Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome. <i>Blood</i> , 2014 , 124, 3808-16	2.2	14
302	Autoantibodies against C1q as a Diagnostic Measure of Lupus Nephritis: Systematic Review and Meta-analysis. <i>Journal of Clinical & Cellular Immunology</i> , 2014 , 5, 210	2.7	14
301	A3.27 Effect of rituximab on different isotypes of serum immunoglobulins in patients with SLE. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A53.1-A53	2.4	1
300	A retrospective study of long-term outcomes in 152 patients with primary Sjögren's syndrome: 25-year experience. <i>Clinical Medicine</i> , 2014 , 14, 157-64	1.9	44
299	Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin. <i>Lupus Science and Medicine</i> , 2014 , 1, e000013	4.6	5
298	Recent developments in the treatment of patients with systemic lupus erythematosus: focusing on biologic therapies. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 311-26	5.4	12

297	The coming of age of adolescent rheumatology. <i>Nature Reviews Rheumatology</i> , 2014 , 10, 187-93	8.1	18
296	Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. <i>Journal of Clinical Investigation</i> , 2014 , 124, 712-24	15.9	99
295	Pathology of systemic lupus erythematosus: the challenges ahead. <i>Methods in Molecular Biology</i> , 2014 , 1134, 1-16	1.4	23
294	Systemic Lupus Erythematosus: Direct B-Cell Blocking. <i>Milestones in Drug Therapy</i> , 2014 , 65-78		1
293	Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. <i>Lancet, The</i> , 2013 , 382, 809-18	4.0	83
292	Cancer risk in systemic lupus: an updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013 , 42, 130-5	15.5	194
291	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2887-97		65
290	Assessment of disease activity, damage and quality of life in systemic lupus erythematosus: new aspects. <i>Best Practice and Research in Clinical Rheumatology</i> , 2013 , 27, 309-18	5.3	26
289	Effect of gender on clinical presentation in systemic lupus erythematosus. <i>Rheumatology</i> , 2013 , 52, 2108-15	8.15	95
288	Reprint of: B cell elimination in systemic lupus erythematosus. <i>Clin. Immunol.</i> 146(2) 90-103. <i>Clinical Immunology</i> , 2013 , 148, 344-58	9	2
287	B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. <i>Arthritis Research and Therapy</i> , 2013 , 15 Suppl 1, S2	5.7	94
286	Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2672-9		90
285	Endothelial microparticle release is stimulated in vitro by purified IgG from patients with the antiphospholipid syndrome. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 72-8	7	16
284	Invariant natural killer T cells are enriched at the site of cutaneous inflammation in lupus erythematosus. <i>Journal of Dermatological Science</i> , 2013 , 71, 22-8	4.3	17
283	CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. <i>Science Translational Medicine</i> , 2013 , 5, 173ra23	17.5	449
282	B cell elimination in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2013 , 146, 90-103	9	33
281	Global trends, potential mechanisms and early detection of organ damage in SLE. <i>Nature Reviews Rheumatology</i> , 2013 , 9, 301-10	8.1	51
280	Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets. <i>European Journal of Clinical Investigation</i> , 2013 , 43, 866-80	4.6	6

279	Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. <i>Arthritis and Rheumatism</i> , 2013 , 65, 3239-47		94
278	Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, 1308-14	2.4	65
277	Autoantibodies against galectins are associated with antiphospholipid syndrome in patients with systemic lupus erythematosus. <i>Glycobiology</i> , 2013 , 23, 12-22	5.8	33
276	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. <i>Rheumatology</i> , 2013 , 52, 1313-22	3.9	98
275	Serum rituximab levels and efficiency of B cell depletion: differences between patients with rheumatoid arthritis and systemic lupus erythematosus. <i>Rheumatology</i> , 2013 , 52, 951-2	3.9	23
274	Dr. Eisenberg replies. <i>Journal of Rheumatology</i> , 2013 , 40, 734	4.1	1
273	B-lymphocyte signalling abnormalities and lupus immunopathology. <i>International Reviews of Immunology</i> , 2013 , 32, 428-44	4.6	8
272	The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey. <i>Rheumatology</i> , 2013 , 52, 2292-301	3.9	58
271	Pathogenesis of neurocognitive and neuropsychiatric manifestations in childhood-onset lupus: an overview. <i>Rheumatology Reports</i> , 2013 , 5, 6		2
270	Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, 896-903	2.2	20
269	Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. <i>Autoimmunity Reviews</i> , 2012 , 11, 357-64	13.6	176
268	Rituximab-it was the best of times, it was the worst of times. <i>Autoimmunity Reviews</i> , 2012 , 11, 790-1	13.6	17
267	The BILAG-2004 systems tally--a novel way of representing the BILAG-2004 index scores longitudinally. <i>Rheumatology</i> , 2012 , 51, 2099-105	3.9	11
266	Lipid-antigen presentation by CD1d(+) B cells is essential for the maintenance of invariant natural killer T cells. <i>Immunity</i> , 2012 , 36, 477-90	32.3	150
265	Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3129-38		112
264	Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1771-82	2.4	692
263	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2677-86		2688
262	B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels. <i>Rheumatology</i> , 2012 , 51, 1208-15	3.9	49

243	Assessment of a lupus nephritis cohort over a 30-year period. <i>Rheumatology</i> , 2011 , 50, 1424-30	3.9	99
242	p185, an immunodominant epitope, is an autoantigen mimotope. <i>Journal of Biological Chemistry</i> , 2011 , 286, 26220-7	5.4	5
241	The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: an evaluation. <i>Rheumatology</i> , 2011 , 50, 1401-8	3.9	67
240	Interrater reliability and aspects of validity of the myositis damage index. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1272-6	2.4	18
239	Primary Sjögren's syndrome activity and damage indices comparison. <i>European Journal of Clinical Investigation</i> , 2010 , 40, 636-44	4.6	22
238	Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. <i>Rheumatology</i> , 2010 , 49, 128-40	3.9	224
237	Numerical scoring for the BILAG-2004 index. <i>Rheumatology</i> , 2010 , 49, 1665-9	3.9	84
236	Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. <i>Rheumatology</i> , 2010 , 49, 691-6	3.9	18
235	The LupusQoL and associations with demographics and clinical measurements in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2010 , 37, 2273-9	4.1	44
234	Green tea polyphenol epigallocatechin gallate inhibits cell signaling by inducing SOCS1 gene expression. <i>International Immunology</i> , 2010 , 22, 359-66	4.9	13
233	Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts. <i>Rheumatology</i> , 2010 , 49, 1502-4	3.9	46
232	Assessment of patients with primary Sjögren's syndrome--outcome over 10 years using the Sjögren's Syndrome Damage Index. <i>Rheumatology</i> , 2010 , 49, 1559-62	3.9	13
231	Estimating indirect costs in primary Sjögren's syndrome. <i>Journal of Rheumatology</i> , 2010 , 37, 1010-5	4.1	34
230	Thirty years, five hundred patients: some lessons learned from running a lupus clinic. <i>Lupus</i> , 2010 , 19, 667-74	2.6	5
229	Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. <i>Journal of Immunology</i> , 2010 , 184, 6622-8	5.3	58
228	Rituximab as early therapy for pulmonary haemorrhage in systemic lupus erythematosus. <i>Rheumatology</i> , 2010 , 49, 392-4	3.9	39
227	The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE. <i>Rheumatology</i> , 2010 , 49, 723-32	3.9	63
226	Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. <i>Journal of Rheumatology</i> , 2010 , 37, 322-9	4.1	65

225	Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis. <i>Rheumatology</i> , 2010 , 49, 960-71	3.9	82
224	Abnormal CTLA-4 function in T cells from patients with systemic lupus erythematosus. <i>European Journal of Immunology</i> , 2010 , 40, 569-78	6.1	44
223	Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. <i>Arthritis and Rheumatism</i> , 2010 , 62, 211-21		106
222	Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. <i>Arthritis and Rheumatism</i> , 2010 , 62, 222-33		866
221	Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010 , 62, 845-54		88
220	Protein phosphorylation and kinome profiling reveal altered regulation of multiple signaling pathways in B lymphocytes from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2412-23		34
219	"Muscles and bones". <i>Arthritis and Rheumatism</i> , 2010 , 62, 2616-8		
218	CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. <i>Immunity</i> , 2010 , 32, 129-40	32.3	1140
217	Childhood- and adult-onset lupus: an update of similarities and differences. <i>Expert Review of Clinical Immunology</i> , 2009 , 5, 391-403	5.1	61
216	Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2009 , 20, 1103-12	12.7	718
215	Thrombin binding predicts the effects of sequence changes in a human monoclonal antiphospholipid antibody on its in vivo biologic actions. <i>Journal of Immunology</i> , 2009 , 182, 4836-43	5.3	18
214	B-cell-depletion therapy in SLE--what are the current prospects for its acceptance?. <i>Nature Reviews Rheumatology</i> , 2009 , 5, 711-6	8.1	53
213	Numerical scoring for the Classic BILAG index. <i>Rheumatology</i> , 2009 , 48, 1548-52	3.9	31
212	Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. <i>Rheumatology</i> , 2009 , 48, 673-5	3.9	160
211	The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. <i>Rheumatology</i> , 2009 , 48, 691-5	3.9	74
210	Selective targeting of B cells with agonistic anti-CD40 is an efficacious strategy for the generation of induced regulatory T2-like B cells and for the suppression of lupus in MRL/lpr mice. <i>Journal of Immunology</i> , 2009 , 182, 3492-3502	5.3	236
209	Impaired C3b/iC3b deposition on <i>Streptococcus pneumoniae</i> in serum from patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2009 , 48, 1498-501	3.9	12
208	Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2009 , 9, 82-9	13.6	54

207	Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009 , 23, 563-74	5.3	8
206	Respiratory manifestations of systemic lupus erythematosus: old and new concepts. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009 , 23, 469-80	5.3	86
205	A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. <i>Arthritis and Rheumatism</i> , 2009 , 61, 482-7		204
204	Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up. <i>Clinical Rheumatology</i> , 2009 , 28, 947-53	3.9	30
203	Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. <i>Arthritis Research and Therapy</i> , 2009 , 11, R154	5.7	88
202	mAbs in nonlupus autoimmune rheumatic disease. <i>Current Opinion in Hematology</i> , 2009 , 16, 280-4	3.3	1
201	Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2009 , 48, 573-5	3.9	21
200	Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. <i>Rheumatology</i> , 2009 , 48, 594-5	3.9	41
199	Autoimmune diseases. <i>Medicine</i> , 2008 , 36, 279-283	0.6	
198	Systemic lupus erythematosus. <i>New England Journal of Medicine</i> , 2008 , 358, 929-39	59.2	1367
197	Sjögren's syndrome: diagnosis and therapeutic challenges in the elderly. <i>Drugs and Aging</i> , 2008 , 25, 19-33	4.7	13
196	Treating patients with lupus with B-cell depletion. <i>Lupus</i> , 2008 , 17, 400-4	2.6	12
195	Screening autoantibody profiles in systemic rheumatic disease with a diagnostic protein microarray that uses a filtration-assisted nanodot array luminometric immunoassay (NALIA). <i>Clinical Chemistry</i> , 2008 , 54, 883-90	5.5	15
194	Introduction to a systemic lupus erythematosus - biomarkers meeting held at University College London on 23rd and 24th February 2007. <i>Lupus</i> , 2008 , 17, 231	2.6	
193	Chapter 15 Systemic Lupus Erythematosus and Endocrine Disorders. <i>Handbook of Systemic Autoimmune Diseases</i> , 2008 , 9, 173-184	0.3	
192	Therapeutic potential (1). <i>Lupus</i> , 2008 , 17, 259-61	2.6	
191	Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 31-41	5.9	14
190	Conversion of discoid lupus to antiphospholipid syndrome and SLE. <i>Nature Clinical Practice Rheumatology</i> , 2008 , 4, 106-10		

189	B-cell-targeted therapies: promising new treatments for systemic lupus erythematosus. <i>Future Rheumatology</i> , 2008 , 3, 59-68		0
188	Inflammatory muscle disease assessment. <i>Current Rheumatology Reports</i> , 2008 , 10, 328-32	4.9	1
187	Familial clustering of non-nuclear autoantibodies and C3 and C4 complement components in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1116-24		13
186	Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1784-8		49
185	Applicability of the paediatric rheumatology international trials organisation disease activity core set for juvenile dermatomyositis: comment on the article by Ruperto et al. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1197-8; author reply 1198-9		2
184	Reliability and validity of the myositis disease activity assessment tool. <i>Arthritis and Rheumatism</i> , 2008 , 58, 3593-9		58
183	Fifty years of anti-ds DNA antibodies: are we approaching journey's end?. <i>Rheumatology</i> , 2007 , 46, 1052-6	5.9	188
182	Lupus nephritis: assessing the evidence, considering the future. <i>Lupus</i> , 2007 , 16, 210-1	2.6	9
181	Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. <i>Arthritis and Rheumatism</i> , 2007 , 56, 280-90		115
180	Altered lipid raft-associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007 , 56, 291-302		36
179	Natural killer T cells in families of patients with systemic lupus erythematosus: their possible role in regulation of IGG production. <i>Arthritis and Rheumatism</i> , 2007 , 56, 303-10		43
178	The systemic lupus erythematosus Tri-Nation study: cumulative indirect costs. <i>Arthritis and Rheumatism</i> , 2007 , 57, 64-70		51
177	Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome. <i>Arthritis and Rheumatism</i> , 2007 , 56, 2392-401		11
176	Development and validation of a disease-specific health-related quality of life measure, the LupusQoL, for adults with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007 , 57, 972-9		185
175	British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007 , 56, 4113-9		76
174	B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1259-62	2.4	122
173	Agrin signalling contributes to cell activation and is overexpressed in T lymphocytes from lupus patients. <i>Journal of Immunology</i> , 2007 , 179, 7975-83	5.3	10
172	Syndromes and complications of interferon therapy. <i>Current Opinion in Rheumatology</i> , 2007 , 19, 61-6	5.3	62

171	Immunopathogenesis of systemic lupus erythematosus. <i>Future Rheumatology</i> , 2007 , 2, 93-103		
170	Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006 , 54, 1543-56		104
169	Usefulness of the British Isles Lupus Assessment Group index in pediatric clinical trials: comment on the article by Ruperto et al. <i>Arthritis and Rheumatism</i> , 2006 , 54, 2343-4		1
168	Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. <i>Arthritis and Rheumatism</i> , 2006 , 54, 3300-5		77
167	Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study. <i>Arthritis and Rheumatism</i> , 2006 , 55, 892-9		81
166	Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2006 , 55, 900-4		78
165	Systemic lupus erythematosus--2005 annus mirabilis?. <i>Nature Clinical Practice Rheumatology</i> , 2006 , 2, 145-52		19
164	Systemic Lupus International Collaborating Group--onwards and upwards?. <i>Lupus</i> , 2006 , 15, 606-7	2.6	24
163	Atorvastatin restores Lck expression and lipid raft-associated signaling in T cells from patients with systemic lupus erythematosus. <i>Journal of Immunology</i> , 2006 , 177, 7416-22	5.3	106
162	Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. <i>Journal of Immunology</i> , 2006 , 177, 1729-36	5.3	27
161	The origin and pathogenic consequences of anti-dsDNA antibodies in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2006 , 2, 377-85	5.1	11
160	52-kDa Ro/SSA epitopes preferentially recognized by antibodies from mothers of children with neonatal lupus and congenital heart block. <i>Arthritis Research and Therapy</i> , 2006 , 8, R4	5.7	39
159	In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. <i>Arthritis Research and Therapy</i> , 2006 , 8, R13	5.7	90
158	Lessons from Sequence Analysis of Monoclonal Antiphospholipid Antibodies 2006 , 470-491		2
157	A novel expression system of domain I of human beta2 glycoprotein I in Escherichia coli. <i>BMC Biotechnology</i> , 2006 , 6, 8	3.5	30
156	B cell targeted therapies in autoimmune diseases. <i>Journal of rheumatology Supplement, The</i> , 2006 , 77, 24-8		20
155	Beta-2-glycoprotein specificity of human anti-phospholipid antibody resides on the light chain: a novel mechanism for acquisition of cross-reactivity by an autoantibody. <i>Molecular Immunology</i> , 2005 , 42, 39-48	4.3	3
154	Mixed connective tissue disease: still crazy after all these years. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 421-36, v	2.4	33

153	Stable expression of a recombinant human antinucleosome antibody to investigate relationships between antibody sequence, binding properties, and pathogenicity. <i>Arthritis Research and Therapy</i> , 2005 , 7, R971-83	5.7	13
152	The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin. <i>Arthritis Research</i> , 2005 , 7, R47-56		17
151	Lupus autoantibodies to native DNA preferentially bind DNA presented on PolIV. <i>Immunology</i> , 2005 , 114, 418-27	7.8	6
150	Imaging in CNS lupus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005 , 19, 727-39	5.3	28
149	Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005 , 52, 3955-65		96
148	BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group disease activity index for patients with systemic lupus erythematosus. <i>Rheumatology</i> , 2005 , 44, 902-6	3.9	363
147	Cyclophosphamide: Time to Say Goodnight and Goodbye?. <i>Current Rheumatology Reviews</i> , 2005 , 1, 189-196		
146	Autoimmunity in Systemic Lupus Erythematosus 2005 , 505-514		
145	Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. <i>Journal of Experimental Medicine</i> , 2004 , 200, 277-85	16.6	991
144	Anti-dsDNA antibodies: still a useful criterion for patients with systemic lupus erythematosus?. <i>Lupus</i> , 2004 , 13, 881-5	2.6	25
143	International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. <i>Rheumatology</i> , 2004 , 43, 49-54	3.9	249
142	Common patterns of B cell perturbation and expanded V4-34 immunoglobulin gene usage in autoimmunity and infection. <i>Autoimmunity</i> , 2004 , 37, 9-15	3	32
141	Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis?. <i>Arthritis and Rheumatism</i> , 2004 , 50, 866-70		78
140	Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. <i>Human Molecular Genetics</i> , 2004 , 13, 137-47	5.6	223
139	Fine binding characteristics of human autoantibodies?partial molecular characterization. <i>Molecular Immunology</i> , 2004 , 41, 495-495	4.3	
138	Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. <i>Current Opinion in Pharmacology</i> , 2004 , 4, 398-402	5.1	72
137	Thrombotic risk in patients submitted to splenectomy for systemic lupus erythematosus and antiphospholipid antibody syndrome-related thrombocytopenia. <i>European Journal of Internal Medicine</i> , 2004 , 15, 162-167	3.9	21
136	Somatic mutations to arginine residues affect the binding of human monoclonal antibodies to DNA, histones, SmD and Ro antigen. <i>Molecular Immunology</i> , 2004 , 40, 745-58	4.3	15

135	Fine binding characteristics of human autoantibodies-partial molecular characterization. <i>Molecular Immunology</i> , 2004 , 41, 495-510	4.3	4
134	Inflammatory Muscle Diseases: Pathogenesis and Clinical Features. <i>Handbook of Systemic Autoimmune Diseases</i> , 2004 , 3, 107-128	0.3	
133	Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2004 , 113, 1176-1187	15.9	144
132	Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2004 , 113, 1176-87	15.9	71
131	Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. <i>Journal of Rheumatology</i> , 2004 , 31, 2390-4	4.1	31
130	Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. <i>British Journal of Rheumatology</i> , 2003 , 42, 230-4		69
129	Relative Importance of Different Human aPL Derived Heavy and Light Chains in the Binding of aPL to Cardiolipin. <i>Clinical Science</i> , 2003 , 104, 47P-47P		
128	A systematic analysis of sequences of human antiphospholipid and anti-beta2-glycoprotein I antibodies: the importance of somatic mutations and certain sequence motifs. <i>Seminars in Arthritis and Rheumatism</i> , 2003 , 32, 246-65	5.3	30
127	Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003 , 48, 1343-54		74
126	How do antiphospholipid antibodies bind beta2-glycoprotein I?. <i>Arthritis and Rheumatism</i> , 2003 , 48, 2111-21		50
125	Systemic lupus erythematosus measures: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Measure (SLEDAI), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology-Damage Index		15
124	Diagnostic criteria for polymyositis and dermatomyositis. <i>Lancet, The</i> , 2003 , 362, 1762-3; author reply 1763	4.0	51
123	Relative importance of different human aPL derived heavy and light chains in the binding of aPL to cardiolipin. <i>Molecular Immunology</i> , 2003 , 40, 49-60	4.3	25
122	Anti-cardiolipin/beta-2 glycoprotein activities co-exist on human anti-DNA antibody light chains. <i>Molecular Immunology</i> , 2003 , 40, 517-30	4.3	7
121	B cell depletion in autoimmune disease. <i>Arthritis Research</i> , 2003 , 5 Suppl 4, S17-21		40
120	Pregnancy outcome in adult-onset idiopathic inflammatory myopathy. <i>British Journal of Rheumatology</i> , 2003 , 42, 1168-72		118
119	Defining Clinical Improvement in Adult and Juvenile Myositis. <i>Journal of Rheumatology</i> , 2003 , 30, 603-174.1		108
118	What's new in Autoimmune rheumatic diseases. <i>Medicine</i> , 2002 , 30, 1-4	0.6	

117	Optimisation of herpes simplex virus-based vectors for delivery to human peripheral blood mononuclear cells. <i>Journal of Immunological Methods</i> , 2002 , 270, 235-46	2.5	1
116	Pulmonary hypertension in autoimmune rheumatic diseases: where are we now?. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1997-2009		36
115	An open study of B lymphocyte depletion in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2002 , 46, 2673-7		469
114	The 52 000 MW Ro/SS-A autoantigen in Sjögren's syndrome/systemic lupus erythematosus (Ro52) is an interferon-gamma inducible tripartite motif protein associated with membrane proximal structures. <i>Immunology</i> , 2002 , 106, 246-56	7.8	88
113	Serial analysis of Ro/SSA and La/SSB antibody levels and correlation with clinical disease activity in patients with systemic lupus erythematosus. <i>Scandinavian Journal of Rheumatology</i> , 2002 , 31, 133-139	1.9	35
112	The rate and pattern of organ damage in late onset systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2002 , 29, 913-7	4.1	71
111	Anti-prothrombin antibodies: assay conditions and clinical associations in the anti-phospholipid syndrome. <i>British Journal of Haematology</i> , 2001 , 113, 544-9	4.5	30
110	Increased circulating platelet-leucocyte complexes and platelet activation in patients with antiphospholipid syndrome, systemic lupus erythematosus and rheumatoid arthritis. <i>British Journal of Haematology</i> , 2001 , 115, 451-9	4.5	173
109	Cross-reaction of lupus anti-dsDNA antibodies with protein translation factor EF-2. <i>Clinical Immunology</i> , 2001 , 98, 293-300	9	16
108	Crossreactivity of human anti-dsDNA antibodies to phosphorylcholine: clues to their origin. <i>Journal of Autoimmunity</i> , 2001 , 16, 479-84	15.5	30
107	The importance of somatic mutations in the V(lambda) gene 2a2 in human monoclonal anti-DNA antibodies. <i>Journal of Molecular Biology</i> , 2001 , 307, 149-60	6.5	29
106	Expression of the Fabs of human auto-antibodies in Escherichia coli: optimization and determination of their fine binding characteristics and cross-reactivity. <i>Journal of Molecular Biology</i> , 2001 , 308, 527-39	6.5	18
105	Assessment of inflammatory myositis. <i>Current Opinion in Rheumatology</i> , 2001 , 13, 488-92	5.3	4
104	The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1410-8		54
103	Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1431-42		206
102	Inhibition of caspase-3-mediated poly(ADP-ribose) polymerase (PARP) apoptotic cleavage by human PARP autoantibodies and effect on cells undergoing apoptosis. <i>Journal of Biological Chemistry</i> , 2000 , 275, 9043-6	5.4	91
101	Molecular cloning and expression of the Fabs of human autoantibodies in Escherichia coli. Determination of the heavy or light chain contribution to the anti-DNA/-cardiolipin activity of the Fab. <i>Journal of Biological Chemistry</i> , 2000 , 275, 35129-36	5.4	17
100	Autoantibodies in Systemic Lupus Erythematosus 1999 , 156-162		

99	Structure-function analysis and the molecular origins of anti-DNA antibodies in systemic lupus erythematosus. <i>Expert Reviews in Molecular Medicine</i> , 1999 , 1999, 1-28	6.7	3
98	Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters. <i>Journal of Biological Chemistry</i> , 1999 , 274, 1723-8	5.4	109
97	Immunisation of patients with systemic lupus erythematosus: the current state of play. <i>Lupus</i> , 1999 , 8, 497-501	2.6	22
96	Analysis of B-cell epitopes of the Ro/SS-A autoantigen. <i>Trends in Immunology</i> , 1999 , 20, 234-40		50
95	Naming names! Comment on the article by Smolen and Steiner. <i>Arthritis and Rheumatism</i> , 1999 , 42, 191-6		8
94	Interleukin-10 promoter polymorphism and lupus nephritis: comment on the article by Mok et al. <i>Arthritis and Rheumatism</i> , 1999 , 42, 590-3		9
93	IgG anti-endothelial cell autoantibodies from patients with systemic lupus erythematosus or systemic vasculitis stimulate the release of two endothelial cell-derived mediators, which enhance adhesion molecule expression and leukocyte adhesion in an autocrine manner. <i>Arthritis and Rheumatism</i> , 1999 , 42, 631-40		96
92	Malignant lymphoma in primary Sjögren's syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjögren's Syndrome. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1765-72		404
91	Sequence features of monoclonal antiphospholipid antibodies: comment on the article by Ikematsu et al. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1783-4		
90	Overrepresentation of the Fc gamma receptor type IIA R131/R131 genotype in caucasoid systemic lupus erythematosus patients with autoantibodies to C1q and glomerulonephritis. <i>Arthritis and Rheumatism</i> , 1999 , 42, 1828-32		81
89	Single nucleotide polymorphic haplotypes of the interleukin-10 5' flanking region are not associated with renal disease or serology in Caucasian patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2017-8		34
88	Apoptosis in human autoimmune diseases. <i>International Reviews of Immunology</i> , 1999 , 18, 563-89	4.6	28
87	The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies. <i>Journal of Autoimmunity</i> , 1999 , 12, 137-42	15.5	76
86	Autoimmune rheumatic diseases and the heart. <i>British Journal of Hospital Medicine</i> , 1999 , 60, 95-9		1
85	Myositis overlap syndromes. <i>Current Opinion in Rheumatology</i> , 1999 , 11, 468-474	5.3	16
84	Autoimmune thrombocytopenia in primary antiphospholipid syndrome and systemic lupus erythematosus: the response to splenectomy. <i>Seminars in Arthritis and Rheumatism</i> , 1998 , 28, 20-5	5.3	38
83	Immunoglobulin variable region sequences of human monoclonal anti-DNA antibodies. <i>Seminars in Arthritis and Rheumatism</i> , 1998 , 28, 141-54	5.3	26
82	The regulation of heat shock proteins and their role in systemic lupus erythematosus. <i>Seminars in Arthritis and Rheumatism</i> , 1998 , 28, 155-62	5.3	21

81	Predictors of lymphoma development in primary Sjögren's syndrome. <i>Seminars in Arthritis and Rheumatism</i> , 1998 , 28, 80-7	5.3	105
80	The role of in vitro expression systems in the investigation of antibodies to DNA. <i>Seminars in Arthritis and Rheumatism</i> , 1998 , 28, 130-9	5.3	3
79	Immunopathogenesis of SLE. <i>Baillieres Clinical Rheumatology</i> , 1998 , 12, 385-403		17
78	Zinc is an essential cofactor for recognition of the DNA binding domain of poly(ADP-ribose) polymerase by antibodies in autoimmune rheumatic and bowel diseases. <i>Arthritis and Rheumatism</i> , 1998 , 41, 918-26		31
77	Assessing lupus. <i>Arthritis and Rheumatism</i> , 1998 , 41, 2276-2276		1
76	Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephritis. <i>European Journal of Immunology</i> , 1998 , 28, 339-50	6.1	76
75	Elevation of IL-6 in transgenic mice results in increased levels of the 90 kDa heat shock protein (hsp90) and the production of anti-hsp90 antibodies. <i>Journal of Autoimmunity</i> , 1998 , 11, 249-53	15.5	25
74	The clinical relevance of antibodies to ribosomal P ₀ where are we now?. <i>Japanese Journal of Rheumatology</i> , 1997 , 7, 235-245		
73	Autoantibodies: markers of disease or pathogenic?. <i>Annals of the New York Academy of Sciences</i> , 1997 , 823, 256-62	6.5	11
72	Use of phage expression to analyze regions of a human V4-34(VH4-21)-encoded IgG autoantibody required for recognition of DNA. No involvement of the 9G4 idiotope. <i>Annals of the New York Academy of Sciences</i> , 1997 , 815, 338-41	6.5	
71	Splenic involvement in rheumatic diseases. <i>Seminars in Arthritis and Rheumatism</i> , 1997 , 27, 141-55	5.3	67
70	The clinical relevance of antibodies to ribosomal P ₀ where are we now?. <i>Japanese Journal of Rheumatology</i> , 1997 , 7, 235-245		1
69	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1997 , 40, 809-13		505
68	Human immunodeficiency virus infection in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1997 , 40, 1168-72		49
67	Idiotype manipulation for autoimmune diseases: where are we going?. <i>Autoimmunity</i> , 1996 , 24, 55-63	3	6
66	Functional and modelling studies of the binding of human monoclonal anti-DNA antibodies to DNA. <i>Molecular Immunology</i> , 1996 , 33, 471-83	4.3	60
65	B lymphocyte hyperactivity in families of patients with systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 1996 , 9, 59-65	15.5	20
64	Autoantibody repertoire to Ro/SSA and La/SSB antigens in patients with primary and secondary Sjögren's syndrome. <i>Journal of Autoimmunity</i> , 1996 , 9, 537-44	15.5	26

63	Sequences of monoclonal antiphospholipid antibodies: variations on an anti-DNA antibody theme. <i>Seminars in Arthritis and Rheumatism</i> , 1996 , 26, 515-25	5.3	12
62	Neuroendocrine changes in systemic lupus erythematosus and Sjögren's syndrome. <i>Baillieres Clinical Rheumatology</i> , 1996 , 10, 333-47		2
61	The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1996 , 39, 363-9		1688
60	Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. <i>Kidney International</i> , 1995 , 48, 705-11	9.9	163
59	Dual recognition of lipid A and DNA by human antibodies encoded by the VH4-21 gene: A possible link between infection and lupus. <i>Human Antibodies</i> , 1995 , 6, 52-56	1.3	30
58	Autoantibodies to 90 kD heat-shock protein in sera of breast cancer patients. <i>Lancet, The</i> , 1995 , 345, 126	4.0	29
57	Endorsement and memory bias of self-referential pain stimuli in depressed pain patients. <i>British Journal of Clinical Psychology</i> , 1995 , 34, 267-77	3.6	47
56	Tropical rheumatology. Immunological aspects. <i>Baillieres Clinical Rheumatology</i> , 1995 , 9, 215-29		1
55	Abnormalities in the glycosylation of IgG and its clinical utility. <i>Advances in Experimental Medicine and Biology</i> , 1995 , 376, 179-83	3.6	2
54	Enhanced transcription of the gene encoding the SmN autoantigen in patients with systemic lupus erythematosus does not result in enhanced levels of the SmN protein. <i>Autoimmunity</i> , 1994 , 19, 81-7	3	3
53	The role of hsp90 in SLE. <i>Autoimmunity</i> , 1994 , 19, 211-8	3	21
52	The origin, sequence, structure, and consequences of developing anti-DNA antibodies. A human perspective. <i>Arthritis and Rheumatism</i> , 1994 , 37, 169-80		89
51	Antiribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal. <i>Arthritis and Rheumatism</i> , 1994 , 37, 307-15		120
50	Comparison of a monoclonal and polyclonal anti-idiotypic against a human IgG anti-DNA antibody. <i>Journal of Autoimmunity</i> , 1994 , 7, 349-67	15.5	10
49	HLA association of anti-Ro60 and anti-Ro52 antibodies in Sjögren's syndrome. <i>Journal of Autoimmunity</i> , 1994 , 7, 611-21	15.5	26
48	Sequence analysis and fine specificity of two human monoclonal antibodies to histone H1. <i>Molecular Immunology</i> , 1994 , 31, 269-77	4.3	6
47	Bcl-2 and Fas, molecules which influence apoptosis. A possible role in systemic lupus erythematosus?. <i>Autoimmunity</i> , 1994 , 17, 271-8	3	29
46	Glycosylation of Immunoglobulins. <i>BioDrugs</i> , 1994 , 1, 169-172		1

45	Autoantibodies in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 1994 , 6, 468-73	5.3	6
44	The Expression of Heat Shock Proteins in Systemic Lupus Erythematosus 1994 , 99-129		3
43	Idiotypes of DNA-Binding Autoantibodies: Mapping by Epitope Scanning and Molecular Modelling 1994 , 173-189		1
42	Chronic Infection and Autoimmunity. <i>Medical Science Symposia Series</i> , 1994 , 61-66		
41	Elevated levels of the 90 kD heat shock protein in patients with systemic lupus erythematosus are dependent upon enhanced transcription of the hsp90 beta gene. <i>Journal of Autoimmunity</i> , 1993 , 6, 495-506	15.5	31
40	Utilization of the VH4-21 gene segment by anti-DNA antibodies from patients with systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 1993 , 6, 809-25	15.5	99
39	A review of serological abnormalities in relatives of SLE patients. <i>Lupus</i> , 1993 , 2, 145-50	2.6	29
38	Elevated levels of the 70 kD heat shock protein in patients with systemic lupus erythematosus are not dependent on enhanced transcription of the hsp70 gene. <i>Lupus</i> , 1993 , 2, 297-301	2.6	7
37	Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. <i>Arthritis and Rheumatism</i> , 1993 , 36, 340-7		1275
36	Transcription of the genes encoding the small heat shock protein ubiquitin is unchanged in patients with systemic lupus erythematosus. <i>Autoimmunity</i> , 1992 , 13, 197-200	3	7
35	Does mitogen-induced antibody production by normal blood cells mimic spontaneous production in lupus?. <i>Autoimmunity</i> , 1992 , 13, 285-90	3	2
34	Surface expression of heat shock protein 90 by blood mononuclear cells from patients with systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 1992 , 5, 803-14	15.5	52
33	Agalactosyl IgG: an aid to differential diagnosis in early synovitis. <i>Arthritis and Rheumatism</i> , 1991 , 34, 1425-9		68
32	Autoimmunity associated with infection: leprosy, acute rheumatic fever and Lyme disease. <i>Current Opinion in Immunology</i> , 1991 , 3, 930-5	7.8	19
31	Assessment of common idiotype PR4-Id in serial bleeds from lupus patients. <i>Autoimmunity</i> , 1991 , 9, 7-123		2
30	AIDS virus infection and autoimmunity: a perspective of the clinical, immunological, and molecular origins of the autoallergic pathologies associated with HIV disease. <i>Clinical Immunology and Immunopathology</i> , 1991 , 58, 163-80		89
29	Analysis of factors affecting human hybridoma production. <i>Human Antibodies</i> , 1990 , 1, 160-165	1.3	5
28	DNA antibody idiotypes: an analysis of their clinical connections and origins. <i>International Reviews of Immunology</i> , 1990 , 5, 279-93	4.6	18

27	Spontaneous antibody-secreting cells against DNA and common environmental antigens in systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 1990 , 3, 523-30	15.5	11
26	Comparison of DNA antibody idiotypes in human sera: an international collaborative study of 19 idiotypes from 11 different laboratories. <i>Journal of Autoimmunity</i> , 1990 , 3, 393-414	15.5	47
25	The role of the human anti-DNA idiomorph 16/6 in autoimmunity. <i>Clinical Immunology and Immunopathology</i> , 1989 , 51, 313-25		47
24	Pancreatic disease in the autoimmune rheumatic disorders. <i>Seminars in Arthritis and Rheumatism</i> , 1989 , 19, 158-65	5.3	21
23	The mosaic of autoimmunity. <i>Trends in Immunology</i> , 1989 , 10, 123-6		164
22	Autoantibodies against a nuclear 56 kDa protein: a marker for inflammatory muscle disease. <i>Journal of Autoimmunity</i> , 1989 , 2, 877-88	15.5	27
21	A comparative analysis of disease-associated changes in the galactosylation of serum IgG. <i>Journal of Autoimmunity</i> , 1989 , 2, 101-14	15.5	193
20	A common anti-DNA antibody idiomorph and anti-phospholipid antibodies in sera from patients with schistosomiasis and filariasis with and without nephritis. <i>Journal of Autoimmunity</i> , 1989 , 2, 803-11	15.5	26
19	The role of IgG glycoforms in the pathogenesis of rheumatoid arthritis. <i>Seminars in Immunopathology</i> , 1988 , 10, 231-49		91
18	Mycobacteria and autoimmunity. <i>Trends in Immunology</i> , 1988 , 9, 178-82		118
17	Idiotypes and autoimmunity: a review of their role in human disease. <i>Journal of Autoimmunity</i> , 1988 , 1, 7-30	15.5	18
16	Serial studies of the IgG subclass and functional affinity of DNA antibodies in systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 1988 , 1, 483-94	15.5	41
15	The role of antigen in autoimmune responses with special reference to changes in carbohydrate structure of IgG in rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 1988 , 1, 499-506	15.5	19
14	An analysis of autoimmunity through studies of DNA antibody idiotypes. <i>Autoimmunity</i> , 1988 , 1, 67-75	3	5
13	Prevalence of Ro (SS-A) antibodies in patients with polymyositis. <i>Arthritis and Rheumatism</i> , 1987 , 30, 1320		4
12	The origin and significance of anti-DNA antibodies. <i>Trends in Immunology</i> , 1987 , 8, 279-82		24
11	DNA antibody idiotypes: a review of their genetic, clinical, and immunopathologic features. <i>Seminars in Arthritis and Rheumatism</i> , 1987 , 16, 245-52	5.3	34
10	The endocrinologic associations of the autoimmune rheumatic diseases. <i>Seminars in Arthritis and Rheumatism</i> , 1987 , 17, 58-70	5.3	19

9	Preferential secretion of a common anti-DNA idiotype (16/6 Id) and anti-polynucleotide antibodies by normal mononuclear cells following stimulation with <i>Klebsiella pneumoniae</i> . <i>Immunology Letters</i> , 1986 , 12, 313-9	4.1	46
8	Multispecific monoclonal antibodies. <i>Trends in Immunology</i> , 1986 , 7, 354-5		1
7	The use of hybridomas to analyse autoimmunity. <i>British Medical Bulletin</i> , 1984 , 40, 262-6	5.4	12
6	Multiple serologic reactions and their relationship to clinical activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1984 , 27, 132-8		106
5	Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies. <i>Clinical Immunology and Immunopathology</i> , 1984 , 31, 261-71		156
4	The rheumatologic complications of hematologic disorders. <i>Seminars in Arthritis and Rheumatism</i> , 1983 , 12, 348-58	5.3	6
3	Metabolomics in juvenile-onset SLE: identifying new biomarkers to predict cardiovascular risk		1
2	Sex differences in autoimmunity could be associated with altered regulatory T cell phenotype and lipoprotein metabolism		2
1	Inactive disease in lupus patients is linked to autoantibodies to type-I interferons that normalize blood IFN α and B cell subsets		1